Skip to content
    Clinical Trials

    Hypofractionated salvage radiation shows comparable early safety in phase III trial

    Couñago et alClinical and Translational Radiation Oncology

    Hypofractionated salvage radiation shows comparable early safety in phase III trial
    A prespecified interim analysis of the prospective multicenter phase III URONCOR 06-24 trial evaluated early adverse events and patient-reported outcomes (PROs) among 250 patients receiving salvage radiotherapy (SRT) following radical prostatectomy. Patients received either moderate hypofractionation (n = 175) or conventional fractionation (n = 75; 66–70 Gy in 33–35 fractions). In the hypofractionated cohort, regimens included 62.5 Gy in 25 fractions (80.5%), 65.25 Gy in 29 fractions (7.5%), 60 Gy in 24 fractions (4.6%), and 52.5 Gy in 20 fractions (2.9%), reflecting an equivalent dose in 2-Gy fractions (EQD2) of approximately 65–71 Gy (α/β = 1.5).
    Toxicity was evaluated using CTCAE v5.0, and PROs were assessed via EPIC-26 and EORTC QLQ-C30 instruments at baseline, 3 months, and 6 months. Pelvic nodal irradiation was administered significantly more often in the hypofractionation arm than in the conventional arm (39.4% vs 13.3%, p = 0.001). Over a median follow-up of 12.7 months, incidence of grade ≥2 genitourinary adverse events was 21.7% in the hypofractionation cohort versus 17.3% in the conventional fractionation cohort (p = 0.431). Grade ≥2 gastrointestinal toxicity rates were 10.8% and 4.0%, respectively (p = 0.079). PRO metrics demonstrated no clinically meaningful differences between the two treatment cohorts.
    Multivariable modeling revealed that increasing patient age was linked to higher risk of grade ≥2 genitourinary toxicities, whereas receipt of pelvic nodal irradiation was associated with an elevated risk of grade ≥2 gastrointestinal toxicities. Study authors noted that because fractionation schedules were non-randomized, longer follow-up and adjustment for treatment-selection bias remain necessary before definitive comparative safety determinations can be made.

    Key Takeaways

    • At a median follow-up of 12.7 months, rates of grade ≥2 genitourinary adverse events were 21.7% with moderate hypofractionation versus 17.3% with conventional fractionation (p = 0.431), and grade ≥2 gastrointestinal adverse events occurred in 10.8% versus 4.0% (p = 0.079), with no clinically meaningful differences in patient-reported outcomes.
    • On multivariable analysis, older age significantly correlated with an increased risk of grade ≥2 genitourinary toxicity, whereas pelvic nodal irradiation significantly correlated with an increased risk of grade ≥2 gastrointestinal toxicity.
    Read the original sourceClinical and Translational Radiation Oncology